Clinical Trial Detail

NCT ID NCT03553836
Title Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

skin melanoma

Therapies

Pembrolizumab

Age Groups: senior adult child

No variant requirements are available.